Compugen (CGEN) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Compugen Ltd. has secured a new U.S. patent for its innovative cancer treatment approach, involving the combination of its COM902 antibody with anti-PD-1 and anti-PVRIG antibodies. This patent strengthens Compugen’s intellectual property portfolio in the field of DNAM-1 axis checkpoint inhibitors, potentially enhancing shareholder value. The patent is part of Compugen’s strategy to develop advanced cancer immunotherapies and is valid until at least 2037.
For further insights into CGEN stock, check out TipRanks’ Stock Analysis page.